Intravenous Ferric Saccharate as an Iron Supplement in Dialysis Patients

Nephron

Volumn 72, Issue 3, 1996, Pages 413-417

  Silverberg, D S ^a   Blum, M ^a   Peer, G ^a   Kaplan, E ^a   Iaina, A ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

CAPD; Erythropoietin; Ferric saccharate; Hemodialysis; Iron

Indexed keywords

ANTIANEMIC AGENT; FERRIC HYDROXIDE SUCROSE; IRON SACCHARATE; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DIALYSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMATOCRIT; HEMODIALYSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; IRON THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; DRUG COMBINATIONS; ERYTHROPOIETIN; FEMALE; FERRIC COMPOUNDS; FERRITINS; HUMANS; INJECTIONS, INTRAVENOUS; IRON; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 0030065969     PISSN: 16608151     EISSN: 22353186     Source Type: Journal    
DOI: 10.1159/000188905     Document Type: Article

References (35)

1. Gotloib L, Ludiccr H. Mines M, Ackerman J: iron storage in chronic uremic undialysed patients. Dial Transplant 1983;12:442B-442E.
2. Herbert V: Recommended dietary intakes (RDI)ofiron in humans. Am J Clin Nutr 1987: 45:679-686.
3. Bezwoda WR. Bothwell TH. Charlton RW. Torrance JD. MacPhail AP. Derman DP. Mayet FL: The relative dietary importance of haem and non-haem iron. S Air Med J 1983: 64:552-556.
4. Cannata JB. Gomez-Alonso C. Femandez-Mcnendez MJ. Fernandez-Soto I, McGregor S. Menendez-Fraga P. Brock JH: Iron-uptake in aluminium overload: In vivo and in vitro studies. Nephrol Dial Transplant 1991:6:637-642.
5. Boddy K, Lawson DH. Linton AL. Will G: Iron metabolism in patients with chronic renal failure. Clin Sei 1970;39:115-121.
6. Hocken AG. Marwah PK: Iatrogenic contribution to anemia of chronic renal failure. Lancet 1971;Vol i: 164-165.
7. Eschbach JW, Cook JD. Scribner BH. Finch CA: Iron balance in hemodialysis patients. Ann Intern Med 1977:87:710-713.
8. Eschbach JW. Egrie JC. Downing MR. Browne JK. Adamson JW: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin-results of a combined phase 1 and II clinical trial. N Engl J Med 1987; 316:73-78.
9. Macdougall LC, Hutton RD, Cavill I, Coles GA. Williams JD: Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously. Br Med J 1989; 299:157-158.
10. Van Wyck DB: Iron management during recombinant human erythropoietin therapy. Am J Kidney Dis 1989:14(suppl 1):9-13.
11. Anastassiades EG. Howarth D. Howarth J. Shanks D. Waters HM. Hyde K, Geary CG. Liu Yin JA. Gokal R: Monitoring of iron requirements in renal patients on erythropoietin. Nephrol Dial Transplant 1993:8:846-853.
12. Van Wyck DB. Stivelman JC. Ruiz J. Kurlin LF. Katz MA. Ogden DA: Iron status in patients receiving erythropoietin for dialysis associated anemia. Kidney Int 1989:35:712-716.
13. Hamstra RD. Block MH. Schocket AL: Intravenous iron dextran in clinical medicine. JAMA 1980:243:1726-1731.
14. Auerbach M. Witt D. Toler W. Fierslein M. Lcmer RG, Ballard H: Clinical use of the total dose intravenous infusion of iron dextran. J Lab Clin Med 1988:111:566-570.
15. Pascual J, Tcrucl JL, Liano F, Sureda A. Ortu-no J: Sodium ferric gluconate complex given intravenously for iron deficiency in hemodialysis. Clin Nephrol 1991:35:87.
16. Pascual J, Teruel JL. Liano F. Sureda A, Ortu-no J: Intravenous Fe gluconatc-Na for iron deficient patients on hemodialysis. Nephron 1992:60:121.
17. Allegra V, Mengozzi G. Vasile A: Iron deficiency in maintenance hemodialysis patients: Assessment of diagnosis criteria and of three different iron treatments. Nephron 1991:57:175-182.
18. Grutzmachcr P. Tsobanelis T, Roth P. Werner E, Vlachojannis J. Kaltwasser J, Kurz P. Scheuermann EH. Schoeppe W: Effect of recombinant human erythropoietin on iron balance in maintenance hemodialysis: Theoretical considerations, clinical experience and consequences. Clin Nephrol 1992;38(suppl l):S92-S97.
19. Schaefer RM. Schaefer L: Management of iron substitution during r-Hu EPO therapy in chronic renal failure patients. Ervthropoicsis: New dimensions in the treatment of anemia. 1992:3:71-75.
20. Mcrcuriali F. Zanclla A. Barosi G. Inghilleri G. Biffi E. Vinci A. Colotti MT: Use of erythropoietin to increase the volume of autologous blood donated by orthopedic patients. Transfusion 1993:33:55-60.
21. Camielli V. Montini G. Da Riol R. Dall'Amico R. Cantarutti F: Effect of high doses of human recombinant erythropoietin on the need for blood transfusions in preterm infants. J Pediatr 1992:121:98-102.
22. Raja R. Bloom R. Goldstein M. Johnson R: Ery thropoietin with oral iron in peritoneal and hemodialysis patients. ASAIO J 1993:39: M578-M580.
23. Geerlings W. Tufveson G. Bruner EP. Ehrlich JHH. Fassbinder W. Landais P. Mallick N, Margrciter R, Raine AEG. Rizzoni G. Selwood N: Combined report on regular dialysis and transplantation in Europe XXL Nephrol Dial Transplant 1991;6(suppl 4):5-29.
24. Levin NW. Lazarus JM. Nissenson AR: Maximizing patient benefits with epoetin alla therapy. Am J Kidney Dis 1993;22(suppl 1):3-12.
25. Goodnough LT. Strasburg J. Riddell J. Ver-brugge D. Wish J: Has recombinant human erythropoietin therapy minimized red-cell transfusions in hemodialysis patients? Clin Nephrol 1994;41:303-307.
26. Besarab A. McCrea JB: Evolution of recombinant human erythropoietin usage in clinical practice in the United Slates. ASAIO J 1993: 39:11-18.
27. Granolleras C, Ouïes R. Branger B, Fourcade J, Shalcon S: Iron supplementation of hemodialysis patients receiving recombinant human erythropoietin therapy; in Bauer C. Koch KM, Scigalla P. Wieczorek L: Erythropoietin: Molecular Physiology and Clinical Application. New York, Dekker, 1993. pp 211-218.
28. Suh H, Wahwa NK: Iron dextran treatment in peritoneal dialysis patients in erythropoietin. Adv Periton Dial 1992. vol 8. pp 464-466.
29. Macdougall LC. Tucker B. Thompson J. Tom-son RV. Baker LRL. Raine AEG: Randomized controlled study of iron supplementation in patients treated with erythropoietin (abstract). Nephrol Dial Transplant 1993:8:960.
30. von Hartitzsch B, Kerr DNS: Response to parenteral iron with and without androgen therapy in patients undergoing regular hemodialysis. Nephron 1976;13:430-438.
31. Crockett RE. Baillod RA, Lee BN. Moorhead JF. Stevenson CM. Varghese Z, Shaldon S: Maintenance of fifty patients on intermittent haemodialysis treatment without blood transfusions. Proc Eur Dial Transplant Assoc 1967; 4:17-22.
32. Schustack A. Meshiaj D. Waiss Z. Gotloib L: Intramuscular iron replenishment and replacement combined with testosterone enanthate in maintenance hemodialysis anemia: A followup of up to 8 years on 16 patients. Clin Nephrol 1985:23:303-306.
33. Stewart WK. Fleming LW, Shepherd AMM: Haemoglobin and serum iron responses to periodic intravenous iron dextran infusions during maintenance haemodialysis. Nephron 1976; 17:121-130.
34. Magana L. Dhar SK. Smith F.C, Martinez C: Iron absorption and utilization in maintenance hemodialysis patients: Oral and intravenous routes. Mt Sinai J Med 1984:51:180-183.
35. Geisser P, Baer M. Schaub E: Structurc/histo-toxicity relationship of parenteral iron preparations. Drug Res 1992;42:1439-1452.